EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Bruno J. Messmer
Marko Turina
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jockenhoevel, S.
Right arrow Articles by Turina, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jockenhoevel, S.
Right arrow Articles by Turina, M.
Related Collections
Right arrow Cardiac - pharmacology

Eur J Cardiothorac Surg 2001;19:424-430
© 2001 Elsevier Science NL

Fibrin gel – advantages of a new scaffold in cardiovascular tissue engineering

Stefan Jockenhoevela,b, Gregor Zundb, Simon P. Hoerstrupb, Khaled Chalabia, Jörg S. Sachweha, Lütfü Demircana, Bruno J. Messmera, Marko Turinab

a Clinic for Thoracic and Cardiovascular Surgery, University Hospital Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany
b Clinic for Cardiovascular Surgery, University Hospital Zurich, Zurich, Switzerland

Received 11 October 2000; received in revised form 31 January 2001; accepted 14 February 2001.

Corresponding author. Tel.: +49-24-1808-9956; fax: +49-24-1888-8454
e-mail: stjocki{at}yahoo.com

Objective: The field of tissue engineering deals with the creation of tissue structures based on patient cells. The scaffold plays a central role in the creation of 3-D structures in cardiovascular tissue engineering like small vessels or heart valve prosthesis. An ideal scaffold should have tissue-like mechanical properties and a complete immunologic integrity. As an alternative scaffold the use of fibrin gel was investigated. Methods: Preliminary, the degradation of the fibrin gel was controlled by the supplementation of aprotinin to the culture medium. To prevent tissue from shrinking a mechanical fixation of the gel with 3-D microstructure culture plates and a chemical fixation with poly-L-lysine in different fixation techniques were studied. The thickness of the gel layer was changed from 1 to 3 mm. The tissue development was analysed by light, transmission and scanning electron microscopy. Collagen production was detected by the measurement of hydroxyproline. Injection molding techniques were designed for the formation of complex 3-D tissue structures. Results: The best tissue development was observed at an aprotinin concentration of 20 µg per cc culture medium. The chemical border fixation of the gel by poly-L-lysine showed the best tissue development. Up to a thickness of 3 mm no nutrition problems were observed in the light and transmission electron microscopy. The molding of a simplified valve conduit was possible by the newly developed molding technique. Conclusion: Fibrin gel combines a number of important properties of an ideal scaffold. It can be produced as a complete autologous scaffold. It is moldable and degradation is controllable by the use of aprotinin.

Key Words: Tissue engineering • Autologous human tissue • Cardiovascular • Scaffolds




This article has been cited by other articles:


Home page
J R Soc InterfaceHome page
P. A Janmey, J. P Winer, and J. W Weisel
Fibrin gels and their clinical and bioengineering applications
J R Soc Interface, January 6, 2009; 6(30): 1 - 10.
[Abstract] [Full Text] [PDF]


Home page
Phil Trans R Soc BHome page
P. M Taylor
Biological matrices and bionanotechnology
Phil Trans R Soc B, August 29, 2007; 362(1484): 1313 - 1320.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
I. Vesely
Heart Valve Tissue Engineering
Circ. Res., October 14, 2005; 97(8): 743 - 755.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. I. Turina
Future of heart valve surgery
Eur. J. Cardiothorac. Surg., December 1, 2004; 26(Suppl_1): S8 - S13.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
W.-H. Zimmermann and T. Eschenhagen
Tissue engineering of aortic heart valves
Cardiovasc Res, December 1, 2003; 60(3): 460 - 462.
[Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. Jux, H. Bertram, P. Wohlsein, M. Brugmann, P. Wuboldt, C. Fink, T. Paul, and G. Hausdorf
Experimental ASD closure using autologous cell-seeded interventional closure devices
Cardiovasc Res, January 1, 2002; 53(1): 181 - 191.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2001 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.